Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a pilot study designed to evaluate the effectiveness of continuous glucose monitoring (CGM) within hours of delivery to predict long-term risk of Type 2 Diabetes Mellitus in patients diagnosed with gestational diabetes.
Participants will be provided a CGM within 2 hours after delivery and wear the device for 24 hours. Participants will be instructed to peel off the device after 24 hours. Participants will also be asked to complete two surveys regarding their experience at 1-3 months postpartum and 12-14 months postpartum.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Continuous Glucose Monitor | Other | Administration of a Continuous Glucose Monitor within 2 hours after delivery for 24-hour collection of glycemic data. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Continuous Glucose Monistor | Device | Continuous glucose monitoring sensor that provides 24/7 detailed glycemic information. Participants will wear for 24 hours and then be instructed to peel off. |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical Efficacy Associated with CGM use immediately postpartum as compared to the 2 hr Glucose tolerance test | Regression analysis to assess strength and direction of the relationship between postpartum CGM data and 2 hr GTT | 24 hours postpartum and 1-3 months postpartum |
| Clinical Efficacy Associated with CGM use immediately postpartum as compared to the HbA1c test postpartum | Regression analysis to assess strength and direction of the relationship between postpartum CGM data and HbA1c | 24 hours postpartum and 1-3 months postpartum |
| Measure | Description | Time Frame |
|---|---|---|
| Patient satisfaction with CGM use immediately postpartum to evaluate long term risk | Patient satisfaction will be measured via survey response on following statements using 5 point likert scale
|
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Rujuta Sathe | Contact | 310-794-8893 | RSathe@mednet.ucla.edu | |
| Dana Levin-Lopez, MPH | Contact | 310-794-8893 | dlevinlopez@mednet.ucla.edu |
| Name | Affiliation | Role |
|---|---|---|
| Christina Han, MD | University of California, Los Angeles | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Los Angeles | Recruiting | Los Angeles | California | 90095 | United States |
Not provided
This study will follow a within-subjects design where participants will serve as their own control group.
Not provided
Not provided
Not provided
Not provided
|
| 1-3 months postpartum after glucose tolerance test, 12-24 months postpartum after A1C blood test |